Latest Regulatory Approvals News

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.

Cobre Limited’s December 2024 quarterly report reveals promising copper mineralisation in Botswana and a significant high purity quartz target in Western Australia, supported by a successful $4.6 million capital raise.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

1414 Degrees Ltd reports strong progress in its hydrogen and thermal energy storage projects, securing full funding for commercialisation and advancing key customer agreements. The company is poised to scale its innovative technologies amid ongoing operational enhancements.

Winsome Resources has filed a key Technical Report for its Adina Lithium Project and extended payment terms for the Renard Operation acquisition, marking significant progress in project development and regulatory engagement.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Lendlease has agreed to sell Capella Capital for $235 million and completed the $516 million sale of its US Military Housing business, reinforcing its strategy to streamline operations and reduce funding needs.

Simonds Group Limited has agreed to acquire Dennis Family Homes for an estimated $10 million, significantly broadening its product portfolio and market presence in Victoria and New South Wales. The deal is expected to boost revenue by $200 million in FY26 and be earnings accretive by Q1 FY26.

Lakes Blue Energy reported a $1.5 million quarterly operational spend and completed the $6.5 million sale of its 49% interest in PEP 169, while progressing drilling approvals for the Wombat-5 well in Victoria.

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.

Brookside Energy Ltd delivered a standout quarter in Q4 2024, posting record production growth and a 667% jump in operating cash flow, while completing a major development project ahead of schedule and under budget.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.